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=======

The authors would like to issue an erratum for this article \[[@CR1]\] and declare the following competing interests, which we inadvertently failed to include in our original publication. The authors would like to apologise for this omission.

Notes {#Sec2}
=====

The present study provides an important advance over an earlier report in which almitoylethanolamide alone was used \[[@CR2]\], in that the co-ultramicronized almitoylethanolamide/luteolin composite demonstrates improved potency by an approximate order of magnitude.

The online version of the original article can be found under doi:10.1186/1742-2094-10-91.
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